Andrew Saunders
Chief Tech/Sci/R&D Officer at CellCentric Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William West | M | - |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | 20 years |
| James Robert Mead | M | 46 | 6 years | |
| Neil Pegg | M | - |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | - |
| Lisa Anson | F | - | 6 years | |
| MaryJane Rafii | M | - |
Bioenvision, Inc.
 Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 18 years |
| Andrew Hughes | M | - |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christopher Barry Wood | M | 78 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 8 years |
| Paddy Prendegast | M | - |
Trinity College Dublin
| 5 years |
| Sarah Gordon-Wild | F | - | 3 years | |
| Sean Patrick Mitchell | M | 56 |
Trinity College Dublin
| 5 years |
| Kristen Williams | F | 50 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 3 years |
| Ciaran J. O'Neill | M | - |
Trinity College Dublin
| 6 years |
| Scott Martin | M | - |
Trinity College Dublin
| 5 years |
| Dominic Nicholas Jackson | M | - | 2 years | |
| Brian Farrell | M | - |
Trinity College Dublin
| 7 years |
| Steven Collins | M | - |
Trinity College Dublin
| 9 years |
| Edward Moss-Hughes | M | 58 |
Trinity College Dublin
| 1 years |
| Donagh M. Herlihy | M | 60 |
Trinity College Dublin
| 5 years |
| Colman Stephenson | M | - |
Trinity College Dublin
| 4 years |
| Michael J. Gilligan | M | - |
Trinity College Dublin
| 4 years |
| David Varian | M | - |
Trinity College Dublin
| 4 years |
| Eamonn Sinnott | M | - |
Trinity College Dublin
| 4 years |
| Kenneth Kinsella | M | 58 |
Trinity College Dublin
| 4 years |
| Eoin Grindley | M | - |
Trinity College Dublin
| 4 years |
| Fiona Dawson | F | 58 |
Trinity College Dublin
| 4 years |
| Michael A. Gallagher | M | - |
Trinity College Dublin
| 4 years |
| Jane Robertson | M | - | 3 years | |
| Jim Lowell | M | - |
Trinity College Dublin
| 2 years |
| Tom Burt | M | 45 | 3 years | |
| Paul Ryan | M | 57 |
Trinity College Dublin
| 3 years |
| Paul G. J. O'Connell | M | 53 |
Trinity College Dublin
| 4 years |
| Fergus Lynch | M | - |
Trinity College Dublin
| 3 years |
| Feei Horng Wong | M | 56 |
Trinity College Dublin
| 4 years |
| David Sharpe | M | - |
Trinity College Dublin
| 4 years |
| Kieran McLoughlin | M | - |
Trinity College Dublin
| 4 years |
| Orla Noonan | F | 54 |
Trinity College Dublin
| 4 years |
| Fionnuala Clare Duggan | F | 59 |
Trinity College Dublin
| 5 years |
| Nicholas Adams | M | 60 | 3 years | |
| James O'Gorman | M | - |
Trinity College Dublin
| 3 years |
| James H. Cullen | M | 60 |
Trinity College Dublin
| 4 years |
| Joseph Cooper | M | 66 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 1 years |
| Pearse MacManus | M | - |
Trinity College Dublin
| 4 years |
| James Scibetta | M | 59 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 1 years |
| Maureen J. Ryan | F | 53 |
Trinity College Dublin
| 4 years |
| Sean Hawkshaw | M | 58 |
Trinity College Dublin
| 4 years |
| Paddy Holahan | M | - |
Trinity College Dublin
| 4 years |
| David Clarke | M | - |
Trinity College Dublin
| 4 years |
| Mark Cruise | M | 53 |
Trinity College Dublin
| 4 years |
| Joseph Concannon | M | - |
Trinity College Dublin
| 1 years |
| Ciaran Meghen | M | - |
Trinity College Dublin
| 4 years |
| Paul F. Reid | M | 60 |
Trinity College Dublin
| 4 years |
| Sean H. Reynolds | M | - |
Trinity College Dublin
| 5 years |
| Michael Wood | M | - |
Trinity College Dublin
| 4 years |
| Desmond Cussen | M | - |
Trinity College Dublin
| 4 years |
| Karl van den Bergh | M | - |
Trinity College Dublin
| 4 years |
| Alan Robinson | M | - |
Trinity College Dublin
| 4 years |
| Robert Winters | M | - |
Trinity College Dublin
| 4 years |
| Aidan King | M | 53 |
Trinity College Dublin
| 4 years |
| Hugh Griffith | M | 56 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 5 years |
| Niall Anthony Gallen | M | 58 |
Trinity College Dublin
| 4 years |
| Fui Chan Ten | M | 60 |
Trinity College Dublin
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Ireland | 45 | 73.77% |
| United Kingdom | 10 | 16.39% |
| United States | 6 | 9.84% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Saunders
- Personal Network
